FBRX Forte Biosciences, Inc.
Healthcare$21.94+1.62%ClosedMarket Cap: $304.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
91.47
P/S
0.00
EV/EBITDA
-3.17
DCF Value
$0.47
FCF Yield
-19.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-106.2%
ROA
-112.8%
ROIC
-176.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-22.4M | $-22.1M | $— | — |
| Q4 null | $0.00 | Infinity% | $-24.6M | $-24.8M | $— | — |
| FY null | $0.00 | -Infinity% | $-70.7M | $-69.4M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-18.4M | $-17.7M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-11.6M | $-11.2M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-16.1M | $-15.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-7.4M | $-7.2M | $— | — |
| FY null | $0.00 | -Infinity% | $-36.6M | $-35.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-8.6M | $-8.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-12.8M | $-12.5M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-7.8M | $-7.4M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-6.4M | $-5.9M | $-4.04 | — |